RxDoctor Payments Data

Guy Winzenried, MD

Gastroenterology · Naples, FLNPI 1578500310

Payments from drug & device makers

$4,789in general payments, 2019–2025

Across 195 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$563
  • Boston Scientific$474
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$364
  • Takeda Pharmaceuticals U.S.A., Inc.$309
  • Mauna Kea Technologies, Inc.$287
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$4,67498%
  • Education$1152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,789 in reported general payments places this provider in the 55th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$432,173
Medicare patients
1,270
Services billed
3,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase45$108,033
CreonLipase/Protease/Amylase22$102,481
Mesalamine75$39,422
LinzessLinaclotide31$25,026
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates189$12,337
Famotidine269$4,144
Balsalazide Disodium15$2,884
Pantoprazole Sodium185$2,369
CholestyramineCholestyramine (With Sugar)38$2,001
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine22$1,811
Cholestyramine LightCholestyramine42$1,678
Ursodiol24$1,585
Omeprazole119$1,483
Rabeprazole Sodium34$1,415
Sucralfate47$992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,239$127,50753 claims
Aimmune Therapeutics, Inc.Zenpep$85$108,03345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →